Routine checks in PSC (Dr James Ferguson)
PSC is a complex condition and ideally, your care should be managed by someone with an interest in and experience of PSC. While there is no curative treatment, your doctor can monitor your condition and help manage your symptoms using current clinical practice guidelines for cholestatic liver diseases.
Because of the serious nature of the complications of PSC, you should remain under lifelong follow up with your PSC doctor.
If you start to get more symptoms and your PSC is evolving or becoming complex, you should be referred for expert multi-disciplinary assessment. Patients with early, stable disease can be managed in general clinics.
Your doctor will also discuss with you how he or she will manage your routine PSC healthcare and together you will form a PSC care plan and communicate this to your GP. Your GP should not be expected to know everything about PSC, and therefore it is helpful when your Hepatology/Gastroenterology consultant shares a clear picture of how you will be monitored and what role your GP will play.
Your PSC doctor will also give you information about what to do about concerns and how to contact the clinic.
Once PSC is diagnosed, your doctor will discuss with you and assess:
Your doctor will try to establish how well your liver is functioning and if there are other associated issues to manage. This can be difficult in PSC so doctors use a range of tests such as:
- your MRCP scan to look at the extent of scarring (strictures) in your bile ducts;
- your ultrasound scan to look at the shape of your liver. An abnormal shape can suggest there is scarring in the liver.
- your Fibroscan (if your doctor has access to one) to look at liver stiffness. The level of stiffness is thought to represent the level of scarring in the liver and is more meaningful in PSC if the score is very low (under 7) or high (over 40). Scores in between can be difficult to interpret.
- your blood tests to give an indication of how well your liver is functioning.
All these tests will provide a baseline assessment of your condition and can provide clues about what will happen in the short-term future (that is, over the next few years). Your doctor may use a prognostic scoring system to help assist timing of referral for liver transplant (should it be necessary), referral to a specialist PSC clinic, or for inclusion in research studies. Prognostic scoring is an emerging field of research.
Everyone with PSC should have a risk assessment for osteoporosis.
Why? Bone density reduces at 1% per year for people with PSC 71.
Initial assessment: Discussion about symptoms and a DEXA (DXA) scan.
Frequency: Your doctor should follow current national guidelines for osteoporosis for any treatment or follow-up.
Evidence: EASL Cholestatic Guideline Section 11.3 4.
Everyone with PSC should be assessed for the presence of inflammatory bowel disease (IBD).
Frequency: If no evidence of IBD is found, your doctor will monitor you for the presence of IBD by asking you about possible IBD symptoms at your review appointments, and occasionally will order a colonoscopy, usually every 5 years if there are no IBD symptoms 10. If you have IBD, your doctor will start routine screening for colon cancer (see below).
Evidence: EASL Cholestatic Guideline Section 5.2.1 4.
Everyone with both PSC and IBD should have a total colonoscopy to screen for colon cancer with regular follow up 4.
Why? People with PSC and IBD have an increased risk of colon cancer compared to the general population and those with IBD alone 10. You doctor should follow the ‘high risk’ guidance in the BSG/ACPGBI guidelines for colorectal cancer screening for people with PSC 107.
Initial assessment: Total colonoscopy with colonic biopsies.
Frequency: People with PSC+IBD should have colonoscopies annually.
Gallbladder Cancer Screening
Everyone with PSC should be screened for gallbladder cancer with regular follow-up.*
Why? People with PSC appear to have an increased risk of developing gallbladder polyps. This association is independent of underlying IBD. Gallbladder polyps found in people with PSC may have higher rates of potentially cancerous cells compared to general population 108,109, even in polyps smaller than 1cm. If polyps are identified, referral to the regional hepatobiliary and pancreatic multidisciplinary meeting or Liver Transplant Unit is essential.
Initial assessment: Ultrasound scan.
Frequency: People with PSC should have an annual ultrasound scan to screen for gallbladder cancer.
Evidence: EASL Cholestatic Guideline Section 5.2.2 4.
*unless they have had their gallbladder removed already.
Liver Cancer Screening
Everyone with PSC should be screened for liver cancer (HCC) with regular follow-up.
Why? Liver cancer is uncommon in PSC, even in the presence of cirrhosis but it is a possibility 109.
Initial assessment: Ultrasound scan
Frequency: People with PSC without the presence of cirrhosis should have an ultrasound scan annually. People with PSC with cirrhosis should have an ultrasound every six months.
Evidence: EASL Cholestatic Guideline Section 5.2.2 4.
Bile Duct Cancer Screening
Bile duct cancer (cholangiocarcinoma, CCA) is a serious complication of PSC and difficult to screen for and diagnose.
Why? People with PSC have a higher risk of developing bile duct cancer than the general population. The majority of CCA cases are identified within one to two years of the PSC diagnosis 110,111.
Initial assessment: Discussion of potential CCA symptoms (sudden upper abdominal pain, elevated CA19-9 blood test, worsening liver blood tests, sudden jaundice ESPECIALLY IN THE FIRST 1-2 YEARS FOLLOWING DIAGNOSIS OF PSC). Where CCA is suspected, referral to the regional hepatobiliary and pancreatic multidisciplinary meeting or Liver Transplant Unit is essential.
Frequency: Raised CA19-9in isolation has weak diagnostic accuracy and is not recommended as part of routine surveillance in the UK. CA19-9 is common in PSC and fluctuates, even in the absence of bile duct cancer. There is little evidence to justify its use for reliable surveillance of CCA. However, CA19-9 monitoring is a personal decision and some people with PSC prefer to have their CA19-9 monitored. Some PSC experts suggest that a surveillance strategy could be MRCP combined with CA19-9 with a cut-off greater than or equal to 129 U/mL 66. The International PSC Study Group is examining surveillance methods in PSC around the world, particularly for bile duct cancer, with the hope that it might show which types may be more superior.
Evidence: EASL Cholestatic Guideline Section 5.2.2 4
Poor nutrition and fat-soluble vitamin deficiency are common in people with PSC.
Why? Advanced bile duct disease means that fat soluble vitamins are not absorbed by the body properly 112. People with advanced PSC should be screened for fat-soluble vitamin deficiencies and supplemented accordingly 113,114. You may have a feeling of ‘unrest’ soon after eating food high in fat: feeling over full after eating, feeling like the food isn’t moving, hearing lots of gurgling sounds, smelly wind, and sometimes even vomiting 114.
It is recommend that the following are considered:
- calcium and vitamin D supplementation in all cholestatic patients as part of the osteoporosis prevention protocol (Section 11.3 Rec 3; Section 11.4 Rec 1 4)
- a supplement vitamins A, E and K enterally in the presence of steatorrhoea (fatty stools) or laboratory evidence of malabsorption (Section 11.4 Rec 2 4)
- vitamin K in overt cholestasis and in the context of bleeding, prior to invasive procedures such as sphincterotomy and/ or stent insertion at ERCP (Section 11.4 Rec 3 4)
Initial assessment: Your doctor will ask you about symptoms relating to fat malabsorption. A blood test can be taken to measure vitamin D, A and E.
Frequency? At each visit to your PSC doctor.
Evidence: EASL Cholestatic Guidelines Section 11.4 4.
For many years, PSC has been poorly understood, and there have been no treatment options other than liver transplantation. There is still no curative treatment for PSC but researchers are working on it.
Professor David Adams, PSC Support Trustee, talked about PSC research in 2015 and said, ‘We are about to enter a very exciting phase where we are going to have new treatments and for some of those I have real hopes will begin to modify this terrible disease.’ We have seen advances in other related diseases over the last 10-15 years such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, giving hope to those affected. Professor Adams continued, ‘I’m hopeful we are entering a phase where the same will apply to PSC.’
It takes on average 17 years from scientific discovery to a new medicine. However, you may have the opportunity to try one of those new drugs now, if you are eligible to take part in a clinical trial.
Not everyone meets the strict criteria to take part, and every trial has slightly different eligibility rules, but we would like to see all patients meeting inclusion criteria offered referral to a centre participating in clinical trials.
Your PSC doctor should be aware of current trials - always ask!